Patients with atopic dermatitis and moderate to severe ocular surface disease who were treated with dupilumab had higher levels of the biologic in their tears than those with mild or no ocular surface disease, according to study results.
Researchers also found dupilumab (Dupixent, Sanofi Genzyme/Regeneron) in conjunctival cell suspensions, Roselie Achten, MSc, MD/PhD candidate of the department of dermatology and allergology at University Medical Center Utrecht, the Netherlands, and colleagues wrote in Clinical and Translational Allergy.
The prospective, monocenter observational cohort study